Lupin launches connected Smart Device-Adhero in India
Lupin has launched 'Adhero', which is the first-of-its-kind, connected smart device in India to track usage pattern of metered dose inhaler (MDI) by patients. The pharma major also announced the rollout of Hydrocortisone Valerate Cream USP, 0.2%, which is for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.
Adhero is a first-of-its-kind device, designed for helping patients with chronic respiratory diseases in tracking their MDI usage and also to facilitate improved adherence to therapy. Since inhalers are the preferred treatment options for managing the increasing incidence of chronic respiratory diseases, such as asthma and COPD, many patients find refilling prescriptions and maintaining the prescribed medication schedule slightly difficult. Here, Adhero comes to play. It is a Bluetooth-enabled reusable smart device that attaches to the top of a MDI. With built-in sensors, the device tracks the patient's daily medication usage and consumption patterns. Patients can have an access to this information by connecting their devices to the ‘MyAdhero’ app on their smartphones.
Lupin had previously received the approval from the United States Food and Drug Administration (USFDA) for Hydrocortisone Valerate Cream USP, 0.2%. It is the generic equivalent of Westcort Cream, 0.2%, by Sun Pharmaceutical Industries Inc. According to IQVIA MAT September 2019 data, Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort Cream) had an annual sales of approximately US$11.5 mn in the U.S markets.
On Friday, the stock of Lupin Ltd. closed at Rs. 773.30, up by 0.33 per cent or Rs. 2.55 per share. The 52-week high is Rs. 905.90 and 52-week low is Rs. 646.20 on BSE.